nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—CHRM3—nephrolithiasis	0.857	1	CbGaD
Solifenacin—Airway obstruction NOS—Hydrochlorothiazide—nephrolithiasis	0.0135	0.206	CcSEcCtD
Solifenacin—Obstructive airways disorder—Hydrochlorothiazide—nephrolithiasis	0.00977	0.149	CcSEcCtD
Solifenacin—CHRM4—Muscarinic acetylcholine receptors—CHRM3—nephrolithiasis	0.00841	0.128	CbGpPWpGaD
Solifenacin—CHRM3—ureter—nephrolithiasis	0.0082	0.704	CbGeAlD
Solifenacin—CHRM5—Muscarinic acetylcholine receptors—CHRM3—nephrolithiasis	0.00806	0.122	CbGpPWpGaD
Solifenacin—CHRM1—Muscarinic acetylcholine receptors—CHRM3—nephrolithiasis	0.00567	0.0861	CbGpPWpGaD
Solifenacin—CHRM2—Muscarinic acetylcholine receptors—CHRM3—nephrolithiasis	0.0056	0.085	CbGpPWpGaD
Solifenacin—Gastrooesophageal reflux disease—Hydrochlorothiazide—nephrolithiasis	0.00246	0.0375	CcSEcCtD
Solifenacin—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.00218	0.0332	CcSEcCtD
Solifenacin—CHRM4—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00186	0.0282	CbGpPWpGaD
Solifenacin—CHRM5—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00178	0.027	CbGpPWpGaD
Solifenacin—Dermatitis exfoliative—Hydrochlorothiazide—nephrolithiasis	0.00171	0.026	CcSEcCtD
Solifenacin—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.0017	0.0259	CcSEcCtD
Solifenacin—Renal impairment—Hydrochlorothiazide—nephrolithiasis	0.00169	0.0258	CcSEcCtD
Solifenacin—CHRM4—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00156	0.0237	CbGpPWpGaD
Solifenacin—CHRM5—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0015	0.0227	CbGpPWpGaD
Solifenacin—Liver function test abnormal—Hydrochlorothiazide—nephrolithiasis	0.00149	0.0227	CcSEcCtD
Solifenacin—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.00148	0.0225	CcSEcCtD
Solifenacin—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.00147	0.0224	CcSEcCtD
Solifenacin—CYP3A4—urine—nephrolithiasis	0.00146	0.126	CbGeAlD
Solifenacin—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.00142	0.0217	CcSEcCtD
Solifenacin—Influenza—Hydrochlorothiazide—nephrolithiasis	0.00139	0.0212	CcSEcCtD
Solifenacin—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.0013	0.0198	CcSEcCtD
Solifenacin—CHRM1—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00125	0.019	CbGpPWpGaD
Solifenacin—CHRM2—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00124	0.0188	CbGpPWpGaD
Solifenacin—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.00122	0.0186	CcSEcCtD
Solifenacin—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00121	0.0184	CcSEcCtD
Solifenacin—CHRM4—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00114	0.0173	CbGpPWpGaD
Solifenacin—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00111	0.0169	CcSEcCtD
Solifenacin—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.0011	0.0167	CcSEcCtD
Solifenacin—CHRM5—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00109	0.0166	CbGpPWpGaD
Solifenacin—CHRM1—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00105	0.016	CbGpPWpGaD
Solifenacin—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00105	0.0161	CcSEcCtD
Solifenacin—CHRM2—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00104	0.0158	CbGpPWpGaD
Solifenacin—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.000949	0.0145	CcSEcCtD
Solifenacin—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.000914	0.0139	CcSEcCtD
Solifenacin—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.000886	0.0135	CcSEcCtD
Solifenacin—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.000857	0.0131	CcSEcCtD
Solifenacin—Cough—Hydrochlorothiazide—nephrolithiasis	0.000846	0.0129	CcSEcCtD
Solifenacin—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.000807	0.0123	CcSEcCtD
Solifenacin—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.000798	0.0122	CcSEcCtD
Solifenacin—CHRM4—G alpha (i) signalling events—RGS14—nephrolithiasis	0.000792	0.012	CbGpPWpGaD
Solifenacin—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.000791	0.0121	CcSEcCtD
Solifenacin—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.000772	0.0118	CcSEcCtD
Solifenacin—CHRM1—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000769	0.0117	CbGpPWpGaD
Solifenacin—CHRM3—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000766	0.0116	CbGpPWpGaD
Solifenacin—CHRM2—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000759	0.0115	CbGpPWpGaD
Solifenacin—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.000703	0.0107	CcSEcCtD
Solifenacin—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.000697	0.0106	CcSEcCtD
Solifenacin—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.000688	0.0105	CcSEcCtD
Solifenacin—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.000682	0.0104	CcSEcCtD
Solifenacin—Constipation—Hydrochlorothiazide—nephrolithiasis	0.000677	0.0103	CcSEcCtD
Solifenacin—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.000652	0.00995	CcSEcCtD
Solifenacin—CHRM3—renal system—nephrolithiasis	0.000652	0.056	CbGeAlD
Solifenacin—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.000647	0.00987	CcSEcCtD
Solifenacin—CHRM3—kidney—nephrolithiasis	0.00063	0.0541	CbGeAlD
Solifenacin—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.000629	0.00959	CcSEcCtD
Solifenacin—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.000626	0.00954	CcSEcCtD
Solifenacin—CHRM5—G alpha (q) signalling events—DGKH—nephrolithiasis	0.000615	0.00934	CbGpPWpGaD
Solifenacin—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.000583	0.00889	CcSEcCtD
Solifenacin—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.000568	0.00866	CcSEcCtD
Solifenacin—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00056	0.00854	CcSEcCtD
Solifenacin—CHRM4—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000557	0.00845	CbGpPWpGaD
Solifenacin—CHRM4—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000557	0.00845	CbGpPWpGaD
Solifenacin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00055	0.00835	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Other—CHRM3—nephrolithiasis	0.00055	0.00835	CbGpPWpGaD
Solifenacin—CHRM5—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000533	0.00809	CbGpPWpGaD
Solifenacin—CHRM5—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000533	0.00809	CbGpPWpGaD
Solifenacin—CHRM2—G alpha (i) signalling events—RGS14—nephrolithiasis	0.000527	0.008	CbGpPWpGaD
Solifenacin—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.000523	0.00798	CcSEcCtD
Solifenacin—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.000503	0.00767	CcSEcCtD
Solifenacin—Rash—Hydrochlorothiazide—nephrolithiasis	0.000499	0.00761	CcSEcCtD
Solifenacin—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.000498	0.0076	CcSEcCtD
Solifenacin—Headache—Hydrochlorothiazide—nephrolithiasis	0.000496	0.00756	CcSEcCtD
Solifenacin—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00047	0.00717	CcSEcCtD
Solifenacin—CHRM5—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.000445	0.00675	CbGpPWpGaD
Solifenacin—CHRM1—G alpha (q) signalling events—DGKH—nephrolithiasis	0.000433	0.00657	CbGpPWpGaD
Solifenacin—CHRM3—G alpha (q) signalling events—DGKH—nephrolithiasis	0.000432	0.00655	CbGpPWpGaD
Solifenacin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.000398	0.00604	CbGpPWpGaD
Solifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.000387	0.00588	CbGpPWpGaD
Solifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.000386	0.00586	CbGpPWpGaD
Solifenacin—CHRM1—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000375	0.0057	CbGpPWpGaD
Solifenacin—CHRM1—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000375	0.0057	CbGpPWpGaD
Solifenacin—CHRM2—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000371	0.00563	CbGpPWpGaD
Solifenacin—CHRM2—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000371	0.00563	CbGpPWpGaD
Solifenacin—CHRM4—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000359	0.00545	CbGpPWpGaD
Solifenacin—CYP3A4—renal system—nephrolithiasis	0.000358	0.0307	CbGeAlD
Solifenacin—CYP3A4—kidney—nephrolithiasis	0.000346	0.0297	CbGeAlD
Solifenacin—CHRM5—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000344	0.00522	CbGpPWpGaD
Solifenacin—CHRM1—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.000313	0.00475	CbGpPWpGaD
Solifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000307	0.00467	CbGpPWpGaD
Solifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000294	0.00447	CbGpPWpGaD
Solifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00028	0.00425	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—RGS14—nephrolithiasis	0.000271	0.00411	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—RGS14—nephrolithiasis	0.000259	0.00394	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—RGS14—nephrolithiasis	0.000246	0.00374	CbGpPWpGaD
Solifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000242	0.00367	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000239	0.00363	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—RGS14—nephrolithiasis	0.000236	0.00358	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—CHRM3—nephrolithiasis	0.000234	0.00355	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—CHRM3—nephrolithiasis	0.000224	0.0034	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—PTH—nephrolithiasis	0.000214	0.00325	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000207	0.00315	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—PTH—nephrolithiasis	0.000205	0.00311	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000205	0.00311	CbGpPWpGaD
Solifenacin—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.000202	0.00307	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—DGKH—nephrolithiasis	0.000183	0.00278	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—RGS14—nephrolithiasis	0.000183	0.00277	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—RGS14—nephrolithiasis	0.000182	0.00276	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—RGS14—nephrolithiasis	0.00018	0.00274	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—DGKH—nephrolithiasis	0.000175	0.00266	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—ADCY10—nephrolithiasis	0.000171	0.00259	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—DGKH—nephrolithiasis	0.000166	0.00252	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—RGS14—nephrolithiasis	0.000166	0.00252	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—RGS14—nephrolithiasis	0.000165	0.00251	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—RGS14—nephrolithiasis	0.000164	0.00249	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—ADCY10—nephrolithiasis	0.000164	0.00249	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—DGKH—nephrolithiasis	0.000159	0.00242	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—CHRM3—nephrolithiasis	0.000158	0.0024	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—CHRM3—nephrolithiasis	0.000156	0.00237	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—RGS14—nephrolithiasis	0.000145	0.00221	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—PTH—nephrolithiasis	0.000144	0.00219	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—PTH—nephrolithiasis	0.000144	0.00219	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—PTH—nephrolithiasis	0.000143	0.00216	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—RGS14—nephrolithiasis	0.000139	0.00211	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000132	0.00201	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000127	0.00192	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—DGKH—nephrolithiasis	0.000123	0.00187	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—DGKH—nephrolithiasis	0.000123	0.00187	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—DGKH—nephrolithiasis	0.000122	0.00185	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—PTH—nephrolithiasis	0.000121	0.00184	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—CHRM3—nephrolithiasis	0.00012	0.00182	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—GRHPR—nephrolithiasis	0.000117	0.00177	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—PTH—nephrolithiasis	0.000116	0.00176	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ADCY10—nephrolithiasis	0.000115	0.00175	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—CHRM3—nephrolithiasis	0.000115	0.00175	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ADCY10—nephrolithiasis	0.000115	0.00174	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ADCY10—nephrolithiasis	0.000114	0.00173	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—DGKH—nephrolithiasis	0.000112	0.0017	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—DGKH—nephrolithiasis	0.000112	0.0017	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—DGKH—nephrolithiasis	0.000111	0.00168	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—PTH—nephrolithiasis	0.00011	0.00167	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—PTH—nephrolithiasis	0.000105	0.0016	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—AGXT—nephrolithiasis	0.000104	0.00158	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—ATP6V0A4—nephrolithiasis	9.82e-05	0.00149	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—DGKH—nephrolithiasis	9.82e-05	0.00149	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—RGS14—nephrolithiasis	9.8e-05	0.00149	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—RGS14—nephrolithiasis	9.77e-05	0.00148	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—RGS14—nephrolithiasis	9.67e-05	0.00147	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—DGKH—nephrolithiasis	9.4e-05	0.00143	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—ATP6V0A4—nephrolithiasis	9.4e-05	0.00143	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—CHRM3—nephrolithiasis	8.92e-05	0.00135	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—APRT—nephrolithiasis	8.85e-05	0.00134	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—SLC26A1—nephrolithiasis	8.85e-05	0.00134	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—CHRM3—nephrolithiasis	8.81e-05	0.00134	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—PTH—nephrolithiasis	8.16e-05	0.00124	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—PTH—nephrolithiasis	8.13e-05	0.00123	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CHRM3—nephrolithiasis	8.1e-05	0.00123	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—PTH—nephrolithiasis	8.05e-05	0.00122	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CHRM3—nephrolithiasis	8e-05	0.00121	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—PTH—nephrolithiasis	7.41e-05	0.00112	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—PTH—nephrolithiasis	7.39e-05	0.00112	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—PTH—nephrolithiasis	7.31e-05	0.00111	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CHRM3—nephrolithiasis	7.1e-05	0.00108	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CHRM3—nephrolithiasis	6.8e-05	0.00103	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—DGKH—nephrolithiasis	6.62e-05	0.001	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ATP6V0A4—nephrolithiasis	6.62e-05	0.001	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ATP6V0A4—nephrolithiasis	6.6e-05	0.001	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—DGKH—nephrolithiasis	6.6e-05	0.001	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ATP6V0A4—nephrolithiasis	6.53e-05	0.000992	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—DGKH—nephrolithiasis	6.53e-05	0.000992	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PTH—nephrolithiasis	6.49e-05	0.000986	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—AQP1—nephrolithiasis	6.31e-05	0.000958	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PTH—nephrolithiasis	6.22e-05	0.000944	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CHRM3—nephrolithiasis	4.79e-05	0.000727	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CHRM3—nephrolithiasis	4.72e-05	0.000717	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GRHPR—nephrolithiasis	4.57e-05	0.000693	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PTH—nephrolithiasis	4.38e-05	0.000665	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PTH—nephrolithiasis	4.36e-05	0.000662	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PTH—nephrolithiasis	4.32e-05	0.000656	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—AGXT—nephrolithiasis	4.07e-05	0.000618	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	3.46e-05	0.000525	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—APRT—nephrolithiasis	3.46e-05	0.000525	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—SPP1—nephrolithiasis	3.26e-05	0.000495	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—SPP1—nephrolithiasis	3.12e-05	0.000474	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—AQP1—nephrolithiasis	2.47e-05	0.000374	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CHRM3—nephrolithiasis	2.23e-05	0.000339	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—SPP1—nephrolithiasis	2.2e-05	0.000334	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—SPP1—nephrolithiasis	2.19e-05	0.000333	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—SPP1—nephrolithiasis	2.17e-05	0.000329	CbGpPWpGaD
